Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia

被引:23
|
作者
Strzelecki, Dominik [1 ]
Podgorski, Michal [2 ]
Kaluzynska, Olga [1 ]
Gawlik-Kotelnicka, Oliwia [1 ]
Stefanczyk, Ludomir [2 ]
Kotlicka-Antczak, Magdalena [1 ]
Gmitrowicz, Agnieszka [3 ]
Grzelak, Piotr [2 ]
机构
[1] Med Univ Lodz, Dept Affect & Psychot Disorders, Cent Clin Hosp, PL-92213 Lodz, Poland
[2] Med Univ Lodz, Dept Radiol Diagnost Imaging, PL-92213 Lodz, Poland
[3] Med Univ Lodz, Dept Adolescent Psychiat, PL-92213 Lodz, Poland
来源
NUTRIENTS | 2015年 / 7卷 / 10期
关键词
sarcosine; glutamate; white matter; frontal lobe; H-1-NMR spectroscopy; schizophrenia; NMDA RECEPTOR HYPOFUNCTION; PREFRONTAL CORTEX; BRAIN ABNORMALITIES; N-ACETYLASPARTATE; GLUTAMATERGIC TRANSMISSION; 1ST-EPISODE SCHIZOPHRENIA; NEGATIVE SYMPTOMS; BIPOLAR DISORDER; TEMPORAL-LOBE; IN-VIVO;
D O I
10.3390/nu7105427
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Dysfunction of the glutamatergic system, the main stimulating system in the brain, has a major role in pathogenesis of schizophrenia. The frontal white matter (WM) is partially composed of axons from glutamatergic pyramidal neurons and glia with glutamatergic receptors. The natural amino acid sarcosine, a component of a normal diet, inhibits the glycine type 1 transporter, increasing the glycine level. Thus, it modulates glutamatergic transmission through the glutamatergic ionotropic NMDA (N-methyl-d-aspartate) receptor, which requires glycine as a co-agonist. To evaluate the concentrations of brain metabolites (NAA, N-acetylaspartate; Glx, complex of glutamate, glutamine, and -aminobutyric acid (GABA); mI, myo-inositol; Cr, creatine; Cho, choline) in the left frontal WM, Proton Nuclear Magnetic Resonance (H-1-NMR) spectroscopy was used. Twenty-five patients randomly chosen from a group of fifty with stable schizophrenia (DSM-IV-TR) and dominant negative symptoms, who were receiving antipsychotic therapy, were administered 2 g of sarcosine daily for six months. The remaining 25 patients received placebo. Assignment was double blinded. H-1-NMR spectroscopy (1.5 T) was performed twice: before and after the intervention. NAA, Glx and mI were evaluated as Cr and Cho ratios. All patients were also assessed twice with the Positive and Negative Syndrome Scale (PANSS). Results were compared between groups and in two time points in each group. The sarcosine group demonstrated a significant decrease in WM Glx/Cr and Glx/Cho ratios compared to controls after six months of therapy. In the experimental group, the final NAA/Cr ratio significantly increased and Glx/Cr ratio significantly decreased compared to baseline values. Improvement in the PANSS scores was significant only in the sarcosine group. In patients with schizophrenia, sarcosine augmentation can reverse the negative effect of glutamatergic system overstimulation, with a simultaneous beneficial increase of NAA/Cr ratio in the WM of the left frontal lobe. Our results further support the glutamatergic hypothesis of schizophrenia.
引用
收藏
页码:8767 / 8782
页数:16
相关论文
共 28 条
  • [1] Supplementation of antipsychotic treatment with sarcosine-GlyT1 inhibitor - causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia
    Strzelecki, Dominik
    Podgorski, Michal
    Kaluzynska, Olga
    Gawlik-Kotelnicka, Oliwia
    Stefanczyk, Ludomir
    Kotlicka-Antczak, Magdalena
    Gmitrowicz, Agnieszka
    Grzelak, Piotr
    NEUROSCIENCE LETTERS, 2015, 606 : 7 - 12
  • [2] Detection of metabolites in the white matter of frontal lobes and hippocampus with proton in first-episode treatment-naive schizophrenia patients
    He, Zong-Ling
    Deng, Wei
    Li, Ming-Li
    Chen, Zhuang-Fei
    Collier, David A.
    Ma, Xiaohong
    Li, Tao
    EARLY INTERVENTION IN PSYCHIATRY, 2012, 6 (02) : 166 - 175
  • [3] Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia
    Bustillo, Juan R.
    Rowland, Laura M.
    Jung, Rex
    Brooks, William M.
    Qualls, Clifford
    Hammond, Roger
    Hart, Blaine
    Lauriello, John
    NEUROPSYCHOPHARMACOLOGY, 2008, 33 (10) : 2456 - 2466
  • [4] Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: Preliminary report
    Fukuzako, H
    Takeuchi, K
    Hokazono, Y
    Fukuzako, T
    Yamada, K
    Hashiguchi, T
    Obo, Y
    Ueyama, K
    Takigawa, M
    Fujimoto, T
    PSYCHIATRY RESEARCH-NEUROIMAGING, 1995, 61 (04) : 193 - 200
  • [5] Proton Magnetic Resonance Spectroscopy During Initial Treatment With Antipsychotic Medication in Schizophrenia
    Juan R Bustillo
    Laura M Rowland
    Rex Jung
    William M Brooks
    Clifford Qualls
    Roger Hammond
    Blaine Hart
    John Lauriello
    Neuropsychopharmacology, 2008, 33 : 2456 - 2466
  • [6] Frontal white matter biochemical abnormalities in first-episode, treatment-naive patients with major depressive disorder: A proton magnetic resonance spectroscopy study
    Wang, Ying
    Jia, Yanbin
    Xu, Guiyun
    Ling, Xueying
    Liu, Sirun
    Huang, Li
    JOURNAL OF AFFECTIVE DISORDERS, 2012, 136 (03) : 620 - 626
  • [7] GABA concentration in schizophrenia patients and the effects of antipsychotic medication: A proton magnetic resonance spectroscopy study
    Tayoshi, Shin'Ya
    Nakataki, Masahito
    Sumitani, Satsuki
    Taniguchi, Kyoko
    Shibuya-Tayoshi, Sumiko
    Numata, Shusuke
    Iga, Jun-ichi
    Ueno, Shu-ichi
    Harada, Masafumi
    Ohmori, Tetsuro
    SCHIZOPHRENIA RESEARCH, 2010, 117 (01) : 83 - 91
  • [8] Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study
    Plitman, Eric
    Chavez, Sofia
    Nakajima, Shinichiro
    Iwata, Yusuke
    Chung, Jun Ku
    Caravaggio, Fernando
    Kim, Julia
    Alshehri, Youssef
    Chakravarty, M. Mallar
    De Luca, Vincenzo
    Remington, Gary
    Gerretsen, Philip
    Graff-Guerrero, Ariel
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2018, 273 : 16 - 24
  • [9] 7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid,Glutamate,and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings
    Thakkar, Katharine N.
    Roesler, Lara
    Wijnen, Jannie P.
    Boer, Vincent O.
    Klomp, Dennis W. J.
    Cahn, Wiepke
    Kahn, Rene S.
    Neggers, Sebastiaan F. W.
    BIOLOGICAL PSYCHIATRY, 2017, 81 (06) : 525 - 535
  • [10] Proton Magnetic Resonance Spectroscopy in the Frontal and Temporal Lobes of Neuroleptic Naive Patients with Schizophrenia
    Kim M Cecil
    Robert E Lenkinski
    Raquel E Gur
    Ruben C Gur
    Neuropsychopharmacology, 1999, 20 : 131 - 140